secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001193125-23-250816
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte and Sutro finalize Form Definitive Agreement; amend license terms
-------------------------------------------------------------------------

- On Sep 28, 2023, Vaxcyte and Sutro mutually agreed on the Form Definitive Agreement to become effective if Vaxcyte exercises the option to source extract.
- Concurrently, the companies entered the 2023 Amendment to the Sutro License Agreement, modifying royalty reductions, IP prosecution, and royalty payment reporting.
- The previously agreed $5.0M cash payment to Sutro remains due within five business days after mutual agreement on the Form Definitive Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523250816/0001193125-23-250816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523250816/d548055d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-250816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer